Ignite Creation Date:
2025-12-24 @ 9:42 PM
Ignite Modification Date:
2025-12-30 @ 9:35 PM
Study NCT ID:
NCT00951132
Status:
WITHDRAWN
Last Update Posted:
2023-02-02
First Post:
2009-08-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy
Sponsor:
University Hospital, Akershus
Organization:
Study Overview
Official Title:
Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy
Status:
WITHDRAWN
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Failure to include patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DECAMERONE
Brief Summary:
The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.
Detailed Description:
Depression is associated with increased risk of cardiovascular disease, in which one possible mechanism is systemic inflammation. Further, patients at high risk of cardiovascular disease, rosuvastatin decreases the risk, especially among patients with increased inflammation. This is a proof-of-concept study to investigate whether the antiinflammatory effect of rosuvastatin is similar in depressive as in patients with cardiovascular disease.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: